Affymetrix Inc. and Partners HealthCare have announced that they have entered into a three-year translational research collaboration to develop microarray-based diagnostics for complex diseases such ...
Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...
Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...
Phoenix, AZ, March 28, 2007—The NIH Neuroscience Microarray Consortium today announced that it has added high-density genotyping on both the Affymetrix and Illumina platforms to its list of services.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix (Nasdaq:AFFX) and Ariosa Diagnostics, Inc. today announced the signing of a multi-year supply agreement covering Affymetrix arrays and instruments to ...
Targeting ER-Golgi homeostasis as a therapeutic strategy in lung cancer. Background: In the routine diagnostic of cancers, the monitoring of the transcriptome and the chromosomal abnormalities becomes ...
An English Court of Appeals decision in November held that Affymetrix (Santa Clara, CA) has a valid license to critical DNA microarray technology developed by Oxford Gene Technology (OGT; Oxford, UK).
Microarray technologies are generating new data at a breathtaking speed. Because of the sheer size of these data and the technical complexity involved in microarray chip designs, it is a challenge to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback